Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients with Type 2 Diabetes: An Asian perspective from the RENAAL study

Diabetes Care

Volumn 27, Issue 4, 2004, Pages 874-879

  Chan, Juliana C N ^a   Wat, Nelson ^b   So, Wing Yee ^a   Lam, Karen S L ^b   Chua, Chin Teong ^c   Wong, Kok Seng ^d   Morad, Zaki ^e   Dickson, Tania Z ^f   Hille, Darcy ^f   Zhang, Zhongxin ^f   Cooper, Mark E ^g   Shahinfar, Shahnaz ^f   Brenner, Barry M ^h   Kurokawa, Kiyoshi ⁱ  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e HOSPITAL KUALA LUMPUR   (Malaysia)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN;

ADULT; AGED; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HORMONE INHIBITION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 12144286279     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.4.874     Document Type: Article

References (26)

1. Morrish NJ, Wang S, Stevens LK, Fuller JH, Keen H: Mortality and causes of death in the WHO Multinational Survey of Vascular Diseases in Diabetes. Diabetologia 44 (Suppl. 2):S14-S21, 2001
2. U.S. Renal Data System. USRDS 2001 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 1998
3. Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G: Regional variations in the incidence of end stage renal failure in Japan. JAMA 284:2622-2624, 2000
4. Lui SF, Ho YW, Chau KF, Leung CB, Choy BY: Hong Kong Renal Registry 1995-1999. Hong Kong J Nephrol 1:53-60, 1999
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 235-259, 2000
6. Tomlinson B, Young RP, Chan JCN, Chan TYK, Critchley JAJH: Pharmacoepidemiology of ACE inhibitor-induced cough. Drug Safety 16:150-151, 1997
7. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuizzi G, Snapinin SM, Zhang Z, Shahnifar S, for the RENAAL study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
8. Keane WF, Brenner BM, DeZeeuw D, Grunfeld J-P, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-1507, 2003
9. Cox DR: Regression models and life tables (with discussion). J R Stat Soc (B) 34:187-220, 1972
10. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Mitch WE, Walser M, Buffington GA, Lemmann J Jr: A simple method of estimating progression of chronic renal failure. Lancet 2:1326-1328, 1976
12. SAS Institute: The mixed procedure. In SAS/STAT Software: Changes and Enhancements Through Release 6.12. Cary, NC, SAS Institute, 1977, p. 573-701
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
14. Bakris GL, Williams M, Dworkin L, Wlliott WK, Epstein M, Toto R, Tuttle K, Douglas J, Hseuh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
15. Lewis EJ, Hunsicker LG, Clarke WR, Beril T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohede R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
16. Chan JCN, Leung WYS, Critchley JAJH: Drug Responsiveness and Side Effects: Lessons From Chinese Population. 3rd ed. Philadelphia, Hanley & Belfus, 2001, p. 447-468
17. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM: Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 26:683-687, 2003
18. Thomas MC, Cooper ME, Shahinfar S, Brenner BM: Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. Kidney Int 63:1577-1579, 2003
19. Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T: A 15 year follow up study of patients with NIDDM in Osaka, Japan: long term prognosis and cause of death. Diabetes Res Clin Pract 34:47-55, 1996
20. Samanta A, Burden AC, Feehally J, Walls JW: Diabetic renal disease: differences between Asians and white patients. BMJ 293:366-367, 1986
21. Chan JCN, Cheung CK, Cheung MYF, Swaminathan R, Critchley JAJH, Cockram CS: Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 18:1013-1014, 1995
22. Lau YL, Chan LC, Chan YY, Ha SY, Yeung CY, Waye JS, Chui DH: Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong: implications for population screening. N Engl J Med 336: 1298-1301, 1997
23. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B: Factors determining glucose tolerance in patients with thalassemia major. J Endocrinol Metab 77:478-483, 1993
24. Loebstein R, Lehotay DC, Luo X, Barfay W, Tyler B, Sher GD: Diabetic nephropathy in hypertransfused patients with beta-thalassemia: the role of oxidative stress. Diabetes Care 21:1306-1309, 1998
25. Lao TT, Ho LF: Alpha-thalassaemia trait and gestational diabetes mellitus in Hong Kong. Diabetologia 44:966-971, 2001
26. Lao TT, Chan PL, Tam KF: Gestational diabetes mellitus in the last trimester: a feature of maternal iron excess? Diabet Med 18:218-223, 2001